At a glance
ClinicalIndex Comparison RecordN/ACompleted· 181 enrolled
Drug / intervention
GORE® EXCLUDER® Endoprosthesisdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of the GORE® EXCLUDER® Endoprosthesis in the Treatment of Infra-renal Abdominal Aortic Aneurysms
In Brief
An observational study evaluating GORE® EXCLUDER® Endoprosthesis for Abdominal Aortic Aneurysm. Completed, enrolled 181 participants across 1 site.
Detailed Summary
This is a French Registry mandated by the French National Health Authority assessing long-term (5-years) safety of the GORE® Excluder® Endoprosthesis in the treatment of infra-renal Abdominal Aortic Aneurysms (AAA).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAbdominal Aortic Aneurysm
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedDec 2014
Primary CompletionSep 2018
Study CompletionOct 2018
TodayJul 2026
First PostedDec 4, 2014
Enrollment StartJul 1, 2012
Primary CompletionSep 26, 2018
Study CompletionOct 5, 2018
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 11.6 years ago
Interventions
GORE® EXCLUDER® Endoprosthesisdevice
Endovascular therapy to treat abdominal aortic aneurysms